November 14, 2024
Medical Disposables and Supplies Limited (MDS)
Unaudited financials for the six months ended September 30, 2024:
Medical Disposables and Supplies Limited (MDS) for the six months ended September 30, 2024, reported a 5% increase in Revenue totaling $1.88 billion compared to $1.79 billion in the corresponding period last year. Revenue for the second quarter had a 5% increase to close at $907.74 million compared to $866.95 million for the comparable quarter of 2023.
Cost of Sales amounted to $1.44 billion (2023: $1.34 billion), this represents an increase of 8% year over year. Consequently, gross profit decreased by 3% to $439.02 million compared to $454.49 million for the six months ended September 30, 2023. The company booked gross profit of $198.38 million for the second quarter versus $219.82 million reported for the similar quarter of 2023.
Administrative expenses increase by 5% to close at $262.95 million (2023: $251.17 million), while Selling and promotional costs decrease by 3% from $155.48 million in 2023 to $151.05 million in the period under review. As a result, total operating costs for the six months ended September 30, 2024, amounted to $438.02 million, a 2% increase relative to $427.48 million reported in 2023.
Operating Profit for the six months ended September 30, 2024, amounted to $7.20 million, a 78% decrease relative to $32.48 million reported in 2023. Operating Loss for the second quarter amounted to $22.15 million (2023: Operating Profit of $8.87 million).
Finance income totalled $44,271, a 50% decrease from the corresponding period last year. (2023: $88,422) while Finance costs totalled $67.83 million, a 1% increase from the corresponding period last year. (2023: $67.37 million)
Loss before tax for the six months ended September 30, 2024, amounted to $47.73 million, a 24% increase relative to $38.57 million reported in 2023. Loss before tax for the second quarter amounted to $53.74 million (2023: Loss before tax of $38.28 million). Loss for the period amounted to $47.73 million, a 24% increase from the Loss for the period of $38.39 million reported in 2023. For the second quarter, Loss for the period was $49.89 million (2023: Los for the period of $38.28 million).
Consequently, Loss Per Share for the six months amounted to $0.14 (2023: LPS: $0.14), while Loss Per Share for the quarter totaled $0.16 (2023: LPS: $0.14). The twelve-month trailing LPS was $1.15, and the number of shares used in these calculations was 263,157,895.
Notably, MDS’s stock price closed the trading period on November 13, 2024, at a price of $2.18 with a negative P/E ratio of 1.89x.
Balance Sheet Highlights:
The company’s assets totalled $2.80 billion; a 6% decrease from $2.98 billion booked in 2023. This decrease was attributable to ‘Inventories’ which amounted to $1.17 billion (2023: $1.42 billion).
Shareholders’ equity was $731.92 million (2023: $1.02 billion), representing a book value per share of $2.78 (2023: $3.89).
Disclaimer:
Analyst Certification – The views expressed in this research report accurately reflect the personal views of Mayberry Investments Limited Research Department about those issuer (s) or securities as at the date of this report. Each research analyst (s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation (s) or view (s) expressed by that research analyst in this research report.
Company Disclosure – The information contained herein has been obtained from sources believed to be reliable, however its accuracy and completeness cannot be guaranteed. You are hereby notified that any disclosure, copying, distribution or taking any action in reliance on the contents of this information is strictly prohibited and may be unlawful. Mayberry may effect transactions or have positions in securities mentioned herein. In addition, employees of Mayberry may have positions and effect transactions in the securities mentioned herein